CN102245604A - 抗病毒化合物 - Google Patents

抗病毒化合物 Download PDF

Info

Publication number
CN102245604A
CN102245604A CN2009801499565A CN200980149956A CN102245604A CN 102245604 A CN102245604 A CN 102245604A CN 2009801499565 A CN2009801499565 A CN 2009801499565A CN 200980149956 A CN200980149956 A CN 200980149956A CN 102245604 A CN102245604 A CN 102245604A
Authority
CN
China
Prior art keywords
independently
carbocyclyl
occurrence
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801499565A
Other languages
English (en)
Chinese (zh)
Inventor
D.A.德盖
P.L.多纳
W.M.凯蒂
C.W.赫钦斯
A.C.克吕格
J.T.兰多夫
C.E.莫特
P.克里什南
N.C.米斯特里
T.J.皮罗特-马蒂亚斯
S.V.帕特尔
X.李
T.N.索尔特维德尔
L.T.奈尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN102245604A publication Critical patent/CN102245604A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2009801499565A 2008-12-23 2009-12-22 抗病毒化合物 Pending CN102245604A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14031808P 2008-12-23 2008-12-23
US61/140318 2008-12-23
PCT/US2009/069188 WO2010075380A1 (en) 2008-12-23 2009-12-22 Anti-viral compounds

Publications (1)

Publication Number Publication Date
CN102245604A true CN102245604A (zh) 2011-11-16

Family

ID=42167446

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801499565A Pending CN102245604A (zh) 2008-12-23 2009-12-22 抗病毒化合物

Country Status (10)

Country Link
US (2) US8546405B2 (https=)
EP (1) EP2367823A1 (https=)
JP (1) JP2012513410A (https=)
CN (1) CN102245604A (https=)
CA (1) CA2740195A1 (https=)
MX (1) MX2011006333A (https=)
RU (1) RU2505539C2 (https=)
SG (1) SG172353A1 (https=)
WO (1) WO2010075380A1 (https=)
ZA (1) ZA201105356B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
CN102459165B (zh) * 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
UA118080C2 (uk) * 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
MX2013004655A (es) 2010-10-26 2013-08-27 Presidio Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103917536B (zh) 2011-10-03 2016-07-06 瑞斯比维特有限公司 1-吡唑基-3-(4-((2-(苯氨基)嘧啶-4-基)氧基)萘-1-基)脲用作p38 MAP激酶抑制剂
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP2970190A1 (en) 2013-03-14 2016-01-20 Respivert Limited Kinase inhibitors
JP6223563B2 (ja) 2013-10-14 2017-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
CN105636945B (zh) 2013-10-14 2017-11-17 卫材R&D管理有限公司 选择性取代的喹啉化合物
EP3076968B1 (en) 2013-12-02 2019-04-17 ChemoCentryx, Inc. Ccr6 compounds
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
KR20200087273A (ko) 2014-10-24 2020-07-20 란도스 바이오파마, 인크. 란티오닌 합성효소 c-유사 2-계 치료제
CN110494432B (zh) 2016-12-28 2022-08-12 米尼奥尔克斯治疗有限公司 异喹啉化合物，其制备方法及其在与β-半乳糖苷酶活性改变相关的病症中的治疗用途
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
BR112022002387A2 (pt) 2019-12-20 2022-09-06 Landos Biopharma Inc Composto da fórmula z-y-q-y' ou um sal ou éster farmaceuticamente aceitável do mesmo
US12234578B2 (en) 2020-01-29 2025-02-25 Wisconsin Alumni Research Foundation Tannin composite fibers
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
SMT202500271T1 (it) 2020-07-02 2025-09-12 Incyte Corp Composti di urea triciclici come inibitori di v617f di jak2
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
CN119173514A (zh) 2022-03-17 2024-12-20 因赛特公司 作为jak2 v617f抑制剂的三环脲化合物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE75755C (de) * 1894-06-14 DAHL & COMP, in Barmen Verfahren zur Darstellung von aromatisch substituirten Amidodinaphtylmethanen.
WO2004031195A1 (en) * 2002-10-07 2004-04-15 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
WO2006033703A1 (en) * 2004-07-27 2006-03-30 Gilead Sciences, Inc. Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
WO2007076034A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
WO2007076035A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
WO2007081517A2 (en) * 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
WO2008064218A2 (en) * 2006-11-21 2008-05-29 Smithkline Beecham Corporation Amido anti-viral compounds
WO2008133753A2 (en) * 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027627A1 (en) 1993-05-24 1994-12-08 Smithkline Beecham Corporation Hemoregulatory peptides
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5935982A (en) * 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US6235493B1 (en) * 1997-08-06 2001-05-22 The Regents Of The University Of California Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue
CZ289425B6 (cs) 1998-05-20 2002-01-16 Eli Lilly And Company Imidazo[1,2-a] pyridinové sloučeniny, jejich pouľití a farmaceutický přípravek s jejich obsahem
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6369091B1 (en) * 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
RU2236220C2 (ru) 1998-05-22 2004-09-20 Аванир Фармасьютикэлз Аналоги бензимидазола в качестве понижающих регуляторов ige
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
WO2001046196A1 (en) 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
HK1052509B (en) 2000-08-14 2007-09-07 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
EP1341788B1 (en) * 2000-12-15 2005-08-10 Glaxo Group Limited Pyrazolopyridines
JP4169246B2 (ja) * 2001-03-16 2008-10-22 富士フイルム株式会社 ヘテロ環化合物及びそれを用いた発光素子
CN101624391A (zh) * 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
RU2286343C2 (ru) 2001-08-10 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP3925265B2 (ja) 2002-03-25 2007-06-06 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子及びそれを用いた表示装置
MXPA04012642A (es) 2002-06-14 2005-03-23 Merck & Co Inc Inhibidores de la cinesina mitotica.
US20040142993A1 (en) * 2002-07-01 2004-07-22 Carlo Battistini Inhibitors of HCV NS5B polymerase
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2004014852A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
GB0229518D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
TW200508224A (en) * 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7132426B2 (en) 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
WO2005026129A1 (en) 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
CA2543696A1 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
CA2545422C (en) 2003-12-03 2015-06-02 Cytopia Research Pty Ltd Tubulin inhibitors
EP1765332A2 (en) 2004-06-17 2007-03-28 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007001661A (es) 2004-08-13 2007-04-23 Praecis Pharm Inc Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
GB0501964D0 (en) * 2005-01-31 2005-03-09 Arrow Therapeutics Ltd Chemical compounds
CN101146793A (zh) * 2005-02-16 2008-03-19 先灵公司 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US20060235036A1 (en) 2005-04-15 2006-10-19 Doherty Elizabeth M Vanilloid receptor ligands and their use in treatments
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
JP2009501217A (ja) 2005-07-15 2009-01-15 アストラゼネカ アクチボラグ 治療薬
BRPI0619733A2 (pt) 2005-12-12 2011-10-11 Genelabs Tech Inc compostos antivirais de n-(anel aromático de 6 membros)-amido
BRPI0619730A2 (pt) 2005-12-12 2011-10-11 Genelabs Tech Inc compostos antivirais de n-(anel aromático de 5 membros)-amido
CA2634699A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
WO2007082554A1 (en) 2006-01-23 2007-07-26 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Modulators of hcv replication
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
MX2008015662A (es) 2006-06-08 2009-01-12 Lilly Co Eli Nuevos receptores antagonistas de la hormona concentradora de melanina (mch).
ES2392104T3 (es) 2006-06-16 2012-12-04 Syngenta Participations Ag Derivados de carboxamida etenílica útiles como microbiocidas
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7745636B2 (en) * 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US20100055071A1 (en) * 2006-11-21 2010-03-04 Martin Robert Leivers Anti-Viral Compounds
WO2008074450A2 (en) 2006-12-20 2008-06-26 Nicox S.A. Non-peptidic renin inhibitors nitroderivatives
JP5454943B2 (ja) 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CL2008001631A1 (es) 2007-06-06 2009-01-02 Smithkline Beecham Corp Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.
WO2009003009A1 (en) 2007-06-26 2008-12-31 Enanta Pharmaceuticals, Inc. Substituted pyrrolidine as anti-infectives
EP2185154A2 (en) 2007-08-03 2010-05-19 Schering Corporation Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US20090047247A1 (en) 2007-08-13 2009-02-19 Yao-Ling Qiu Pyrrolidine Derivatives
GB0801199D0 (en) 2008-01-23 2008-02-27 Acal Energy Ltd Fuel cells
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
JP2011511841A (ja) 2008-02-12 2011-04-14 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
ATE551337T1 (de) 2008-02-12 2012-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
HRP20120706T1 (hr) 2008-02-13 2012-09-30 Bristol-Myers Squibb Company Imidazolil bifenil imidazoli kao inhibitori virusa hepatitisa c
US8034966B1 (en) * 2008-02-20 2011-10-11 Cell Viable Corporation Phenoxyisobutyric acid compounds and methods for synthesis
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2009143361A1 (en) 2008-05-22 2009-11-26 Smithkline Beecham Corporation Amido anti-viral compounds
WO2009155709A1 (en) 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
US20100068197A1 (en) * 2008-07-11 2010-03-18 Myriad Pharmaceuticals, Inc. Pharmaceutical compounds as inhibitors of cell proliferation and the use thereof
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010015090A1 (en) 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8946289B2 (en) 2008-11-19 2015-02-03 Duke University Manassatin compounds and methods of making and using the same
JP2010126571A (ja) 2008-11-26 2010-06-10 Toyo Ink Mfg Co Ltd 有機エレクトロルミネッセンス素子材料および有機エレクトロルミネッセンス素子
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
SI2373172T1 (sl) 2008-12-03 2013-12-31 Presidio Pharmaceuticals, Inc. Inhibitorji HCV NS5A
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
KR101411889B1 (ko) 2009-02-27 2014-06-27 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
SG174929A1 (en) 2009-03-27 2011-11-28 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication
WO2010111673A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
SG174883A1 (en) 2009-03-27 2011-11-28 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
WO2010115767A1 (en) 2009-04-08 2010-10-14 Basf Se Pyrrolopyrrole derivatives, their manufacture and use as semiconductors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102459165B (zh) 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
RU2528231C2 (ru) 2009-04-24 2014-09-10 Тиботек Фармасьютикалз Диариловые эфиры
WO2010132538A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
PT3309157T (pt) 2009-05-13 2019-12-02 Gilead Pharmasset Llc Compostos antivirais
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8772505B2 (en) 2009-05-29 2014-07-08 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
UA118080C2 (uk) 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
IN2012DN00999A (https=) 2009-07-16 2015-04-10 Vertex Pharma
CN102471324B (zh) 2009-08-07 2014-12-17 泰博特克药品公司 作为丙型肝炎病毒抑制剂的双苯并咪唑衍生物
CN102482260A (zh) 2009-09-03 2012-05-30 泰博特克药品公司 双-苯并咪唑衍生物
EA201290089A1 (ru) 2009-09-04 2012-09-28 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Химические соединения
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2475254A4 (en) 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
EP2507232B1 (en) 2009-12-04 2019-03-20 National Health Research Institutes Proline derivatives
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
KR20120118008A (ko) 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
WO2011079327A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
MA34013B1 (fr) 2010-01-25 2013-02-01 Enanta Pharm Inc Inhibiteurs du virus de l'hépatite c
WO2011091532A1 (en) 2010-01-28 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
KR20120124495A (ko) 2010-03-04 2012-11-13 이난타 파마슈티칼스, 인코포레이티드 Ｈｃｖ 복제의 억제제로서의 조합 제약 작용제
EA201290882A1 (ru) 2010-03-09 2013-04-30 Мерк Шарп Энд Домэ Корп. Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
CN103038237A (zh) 2010-03-24 2013-04-10 沃泰克斯药物股份有限公司 用于黄病毒感染治疗或预防的类似物
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2011150243A1 (en) 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
EP2580209A4 (en) 2010-06-09 2013-11-06 Presidio Pharmaceuticals Inc INHIBITORS OF HCV NS5A PROTEIN
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
MX2013006828A (es) 2010-12-16 2014-10-14 Abbvie Inc Compuestos antivirales.
MX2013006951A (es) 2010-12-16 2013-10-03 Abbvie Inc Compuestos antivirales.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE75755C (de) * 1894-06-14 DAHL & COMP, in Barmen Verfahren zur Darstellung von aromatisch substituirten Amidodinaphtylmethanen.
WO2004031195A1 (en) * 2002-10-07 2004-04-15 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
WO2006033703A1 (en) * 2004-07-27 2006-03-30 Gilead Sciences, Inc. Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
WO2007076034A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
WO2007076035A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
WO2007081517A2 (en) * 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
WO2008064218A2 (en) * 2006-11-21 2008-05-29 Smithkline Beecham Corporation Amido anti-viral compounds
WO2008133753A2 (en) * 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVID C. SMITH ET AL: "Reissert Compound Chemistry. XXVI. The Syntheses of Bis-benzylisoquinolines.", 《J.HETERCYCLIC CHEM.》 *
J. SCOTT SAWYER ET AL: "Synthetic and Structure/Activity Studies on Acid-Substituted 2-Arylphenols:", 《J. MED. CHEM.》 *
SHUZO TAKAGI ET AL: "ANTIMICROBIAL AGENTS FROM BLETILLA STRIATA", 《PHYROCHEMISRY》 *

Also Published As

Publication number Publication date
CA2740195A1 (en) 2010-07-01
JP2012513410A (ja) 2012-06-14
RU2505539C2 (ru) 2014-01-27
US9249138B2 (en) 2016-02-02
US20140213595A1 (en) 2014-07-31
MX2011006333A (es) 2011-06-27
WO2010075380A1 (en) 2010-07-01
EP2367823A1 (en) 2011-09-28
ZA201105356B (en) 2012-03-28
RU2011130831A (ru) 2013-01-27
SG172353A1 (en) 2011-07-28
US20100160355A1 (en) 2010-06-24
US8546405B2 (en) 2013-10-01

Similar Documents

Publication Publication Date Title
CN102245604A (zh) 抗病毒化合物
EP2367824B1 (en) Anti-viral derivatives of pyrimidine
CN101835780B (zh) 用于治疗病毒感染诸如肝炎的咪唑并[1,2-a]吡嗪化合物
AU2015335694B2 (en) Indole carboxamide compounds useful as kinase inhibitors
JP5906253B2 (ja) 抗ウイルス性化合物
CN102216279B (zh) 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
TW200831513A (en) Anti-viral compounds
CN101247807A (zh) 噻唑化合物及使用方法
CN111163766A (zh) Ahr抑制剂和其用途
CN113166108A (zh) 作为泛素特异性蛋白酶30(usp30)抑制剂的稠合吡咯啉
JP2011510004A (ja) タンパク質キナーゼ阻害剤及びその使用
JP7587886B2 (ja) Ｊａｋキナーゼ阻害剤としての小分子化合物及びその用途
EP4168411A1 (en) Methods and compounds for restoring mutant p53 function
WO2019193159A1 (en) Bumetanide derivatives for the therapy of hyperhidrosis
CN102083826A (zh) 磷脂酰肌醇3-激酶的抑制剂
AU2018326721A1 (en) Compounds and compositions for IRE1 inhibition
JP2023545784A (ja) Ｊａｋキナーゼ阻害剤としての小分子化合物及びその用途
WO2024040768A1 (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
JP2022553284A (ja) Ｔｒｅｋ（ｔｗｉｋ関連ｋ＋チャネル）チャネル機能の阻害剤
CA3197199A1 (en) Compounds and compositions for the treatment of cryptosporidiosis
CN121318828A (zh) 一种炎症小体抑制剂及其应用
CN118666733A (zh) 一类四氢咔唑类小分子化合物在制备抗病毒药物中的用途及制备方法
CN117624126A (zh) 选择性酪氨酸激酶2（tyk2）抑制剂化合物、合成方法及用途
KR20070094949A (ko) 2-(시클릭 아미노카르보닐)인돌린 유도체 및 그것을함유하는 약제학적 조성물
HK1159619B (en) Anti-viral derivatives of pyrimidine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130620

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130620

Address after: Illinois State

Applicant after: ABBVIE company

Address before: Illinois State

Applicant before: Abbott GmbH. & Co. Kg

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20111116